UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


WASHINGTON,
D.C.  20549




FORM
10-Q




x
            QUARTERLY REPORT PURSUANT TO SECTION 13
      OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
  1934




For
      the quarterly period ended June 30,
2010




 ̈
            TRANSITION REPORT PURSUANT TO
      SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934




For
      the transition period from _________________ to
      _________________




Commission
File Number: 333-151212









FIRST CHINA PHARMACEUTICAL
GROUP, INC.


(Exact
name of registrant as specified in its charter)




Nevada
              
              74-3232809(State
      or other jurisdiction of incorporation or organization)
              
              (I.R.S.
      Employer Identification Number)800
      Bellevue Way, Suite 400
                Bellevue, WA  98004
                (Address
      of principal executive offices)(425) 646-2391
                (Registrant’s
      telephone number, including area
code)




Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.   Yes  x  No   ̈




Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such
files).  Yes   ̈  No   ̈




Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company.  See definitions of “larger accelerated filer,” “accelerated
filer” and “smaller reporting company” in Rule 12b-2 of the Exchange
Act.  (Check one):




Large
accelerated filer   ̈    Accelerated
filer   ̈Non-accelerated
filer   ̈Smaller reporting company  x


(Do not
check if a smaller reporting company)




Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes x No  ̈




The
number of shares outstanding of the registrant’s common stock at August 6, 2010
was 45,000,000.










INDEX




PageNumberPART
      I - FINANCIAL INFORMATIONITEM
      1.
                                        FINANCIAL
      STATEMENTS
                                        1Balance
      Sheets as of June 30, 2010 (Unaudited) and March 31, 2010
                                        2Statements
      of Operations for the Three Months Ended June 30, 2010 and
      2009and
      for the period from July 21, 2007 (inception) through June 30, 2010
      (Unaudited)
                                        3Statements
      of Stockholders’ Equity (Deficit) for the period from July 21,
      2007(inception)
      through June 30, 2010 (Unaudited)
                                        4Statements
      of Cash Flows for the Three Months Ended June 30, 2010 and
      2009and
      for the period from July 21, 2007 (inception) through June 30, 2010
      (Unaudited)
                                        5Notes
      to Unaudited Financial Statements
                                        6ITEM
      2.
                                        MANAGEMENT’S
      DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
      OPERATIONS
                                        12ITEM
      3.
                                        QUANTITATIVE
      AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS
                                        14ITEM
      4.
                                        CONTROLS
      AND PROCEDURES
                                        14PART
      II - OTHER INFORMATIONITEM
      1.
                                        LEGAL
      PROCEEDINGS
                                        16ITEM
      1A.
                                        RISK
      FACTORS
                                        16ITEM
      2.
                                        UNREGISTERED
      SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
                                        16ITEM
      3.
                                        DEFAULTS
      UPON SENIOR SECURITIES
                                        16ITEM
      4.
                                        REMOVED
      AND RESERVED
                                        16ITEM
      5.
                                        OTHER
      INFORMATION
                                        16ITEM
      6.
                                        EXHIBITS
                                        16SIGNATURES
                                        17




i


PART
I. FINANCIAL INFORMATION




ITEM
      1.
            FINANCIAL
      STATEMENTS




The
accompanying balance sheets of First China Pharmaceutical Group, Inc. as of June
30, 2010 (with comparative figures as of March 31, 2010) and the statements of
operations for each of the three months ended June 30, 2010 and 2009, the
statements of changes in stockholders’ equity (deficit) for each of the three
months ended June 30, 2010 and 2009, and the statements of cash flows for each
of the three months ended June 30, 2010 and 2009 have been prepared by the
Company’s management in conformity with accounting principles generally accepted
in the United States of America.  In the opinion of management, all
adjustments considered necessary for a fair presentation of the results of
operations and financial position have been included and all such adjustments
are of a normal recurring nature.




Operating
results for the quarter ended June 30, 2010 are not necessarily indicative of
the results that can be expected for the year ending March 31,
2011.




1


First
China Pharmaceutical Group, Inc.


(Formerly
E-Dispatch Inc.)


(A
Development Stage Company)


Balance
Sheets





June 30,
                      2010
                    
                    
                    March 31,
                      2010(Unaudited)Assets:Cash
                    
                    $
                    27
                    
                    
                    $
                    7,331Prepaid
      expenses
                    
                    
                    17
                    
                    
                    
                    233Total
      Current Assets
                    
                    
                    44
                    
                    
                    
                    7,564Total
      Assets
                    
                    $
                    44
                    
                    
                    $
                    7,564Liabilities:Accounts
      payable and accrued liabilities
                    
                    $
                    10,250
                    
                    
                    $
                    14,663Due
      to related party
                    
                    
                    12,752
                    
                    
                    
                    11,512Total
      Current Liabilities
                    
                    
                    23,002
                    
                    
                    
                    26,175Total
      Liabilities
                    
                    
                    23,002
                    
                    
                    
                    26,175Stockholders’
      Deficit:Common
      stock, $0.001 par value; 200,000,000 shares authorized;45,000,000
      and 1,800,000 shares issued and outstanding, respectively
                    
                    
                    45,000
                    
                    
                    
                    45,000Additional
      paid in capital
                    
                    
                    5,000
                    
                    
                    
                    5,000Deficit
      accumulated during the development stage
                    
                    
                    (72,958
                    )
                    
                    
                    (68,611
                    )Total
      Stockholders’ Equity (Deficit)
                    
                    
                    (22,958
                    )
                    
                    
                    (18,611
                    )Total
      Liabilities and  Stockholders’ Deficit
                    
                    $
                    44
                    
                    
                    $
                    7,564





See
accompanying notes to the financial statements.


2


First
China Pharmaceutical Group, Inc.


(Formerly
E-Dispatch Inc.)


(A
Development Stage Company)


Statements
of Operations


(Unaudited)




Three
                        Months
                        Ended
                        June 30,
                        2010
                      
                      
                      Three
                        Months
                        Ended
                        June 30,
                        2009
                      
                      
                      For the
                        Period from
                        July 31, 2007
                        (Inception)
                        through
                        June 30,
                        2010Revenue
                      
                      $
                      -
                      
                      
                      $
                      -
                      
                      
                      $
                      -Operating
      expenses:Legal
      and accounting
                      
                      
                      3,863
                      
                      
                      
                      2,250
                      
                      
                      
                      55,588Web
      design
                      
                      
                      -
                      
                      
                      
                      -
                      
                      
                      
                      2,500General
      and administrative
                      
                      
                      484
                      
                      
                      
                      600
                      
                      
                      
                      14,870Total
      operating expenses
                      
                      
                      4,347
                      
                      
                      
                      2,850
                      
                      
                      
                      72,958Loss
      before income taxes
                      
                      
                      (4,347
                      )
                      
                      
                      (2,850
                      )
                      
                      
                      (72,958
                      )Provision
      for income taxes
                      
                      
                      -
                      
                      
                      
                      -
                      
                      
                      
                      -Net
      Loss
                      
                      $
                      (4,347
                      )
                      
                      $
                      (2,850
                      )
                      
                      $
                      (72,958
                      )Basic
      and diluted loss per share
                      
                      $
                      ( 0.00
                      )
                      
                      $
                      (0.00
                      )Weighted
      average number of common shares outstanding
                      
                      
                      45,000,000
                      
                      
                      
                      45,000,000





See
accompanying notes to the financial statements.


3


First
China Pharmaceutical Group, Inc.


(Formerly
E-Dispatch Inc.)


(A
Development Stage Company)


Statements
of Stockholders’ Equity (Deficit)


For
the period from July 31, 2007 (Inception) to June 30, 2010


(Unaudited)





Common Stock
                      
                      
                      Additional
                        Paid in
                      
                      
                      Deficit
                        Accumulated
                        During the
                        DevelopmentShares
                      
                      
                      Amount
                      
                      
                      Capital
                      
                      
                      Stage
                      
                      
                      TotalBalance,
      July 31, 2007 (date of inception)
                      
                      
                      -
                      
                      
                      $
                      -
                      
                      
                      $
                      -
                      
                      
                      $
                      -
                      
                      
                      $
                      -Shares
      issued to founder on July 31, 2007 @ $0.0004 per share (par value $0.001
      per share)
                      
                      
                      25,000,000
                      
                      
                      
                      25,000
                      
                      
                      
                      (15,000
                      )
                      
                      
                      -
                      
                      
                      
                      10,000Private
      placement on November 23, 2007 @ $0.002 per share (par value $0.001 per
      share)
                      
                      
                      20,000,000
                      
                      
                      
                      20,000
                      
                      
                      
                      20,000
                      
                      
                      
                      -
                      
                      
                      
                      40,000Net
      loss
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      (16,998
                      )
                      
                      
                      (16,998
                      )Balance,
      March 31, 2008
                      
                      
                      45,000,000
                      
                      
                      
                      45,000
                      
                      
                      
                      5,000
                      
                      
                      
                      (16,998
                      )
                      
                      
                      21,047Net
      loss
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      (35,083
                      )
                      
                      
                      (35,083
                      )Balance,
      March 31, 2009
                      
                      
                      45,000,000
                      
                      
                      
                      45,000
                      
                      
                      
                      5,000
                      
                      
                      
                      (52,081
                      )
                      
                      
                      (2,081
                      )Net
      loss
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      (16,530
                      )
                      
                      
                      (16,530
                      )Balance,
      March 31, 2010
                      
                      
                      45,000,000
                      
                      
                      
                      45,000
                      
                      
                      
                      5,000
                      
                      
                      
                      (68,611
                      )
                      
                      
                      (18,611
                      )Net
      loss
                      
                      
                      -
                      
                      
                      
                      -
                      
                      
                      
                      -
                      
                      
                      
                      (4,347
                      )
                      
                      
                      (4,347
                      )Balance,
      June 30, 2010
                      
                      
                      45,000,000
                      
                      
                      $
                      45,000
                      
                      
                      $
                      5,000
                      
                      
                      $
                      (72,958
                      )
                      
                      $
                      (22,958
                      )





See
accompanying notes to the financial statements.


4


First
China Pharmaceutical Group, Inc.


(Formerly
E-Dispatch Inc.)


(A
Development Stage Company)


Statements
of Cash Flows


(Unaudited)




Three Months
                  Ended
                  June 30,
                  2010
                
                
                Three Months
                  Ended
                  June 30,
                  2009
                
                
                For the
                  Period from
                  July 31, 2007
                  (Inception)
                  through
                  June 30,
                  2010Operating
      Activities:Net
      loss
                
                $
                (4,347
                )
                
                $
                (2,850
                )
                
                $
                (72,958
                )Adjustments
      to reconcile net loss to net cash used in operating
      activities:Decrease
      (increase) in prepaid expenses
                
                
                216
                
                
                
                598
                
                
                
                (17
                )Increase
      (decrease) in accounts payable and accrued liabilities
                
                
                (4,413
                )
                
                
                689
                
                
                
                10,250Net
      cash used in operating activities
                
                
                (8,544
                )
                
                
                (1,563
                )
                
                
                (62,725
                )Financing
      Activities:Increase
      in due to related party
                
                
                1,240
                
                
                
                -
                
                
                
                12,752Proceeds
      from sale of stock
                
                
                -
                
                
                
                -
                
                
                
                50,000Net
      cash from financing activities
                
                
                1,240
                
                
                
                -
                
                
                
                62,752Net
      change in cash
                
                
                (7,304
                )
                
                
                (1,563
                )
                
                
                27Cash
      at beginning of period
                
                
                7,331
                
                
                
                7,681
                
                
                
                -Cash
      at end of period
                
                $
                27
                
                
                $
                6,118
                
                
                $
                27Supplemental
      Disclosures of Cash Flow Information:Cash
      paid for:Interest
                
                $
                -
                
                
                $
                -
                
                
                $
                -Income
      taxes
                
                $
                -
                
                
                $
                -
                
                
                $
                -





See
accompanying notes to the financial statements.


5





First
China Pharmaceutical Group, Inc.


(Formerly
E-Dispatch Inc.)


(A
Development Stage Company)


June
30, 2010 and 2009


Notes
to the Financial Statements


(Unaudited)





Note
1 – Nature of Operations





First
China Pharmaceutical Group, Inc., formerly E-Dispatch Inc. (the “Company”), a
development stage company, was incorporated on July 31, 2007 under the laws of
the State of Nevada.  Initial operations have included organization
and incorporation, target market identification, new product development,
marketing plans, and capital formation.  A substantial portion of the
Company’s activities has involved developing a business plan and establishing
contacts and visibility in the marketplace.  The Company has not
generated any revenues since inception.  The Company plans to engage
in cell phone based taxi dispatch systems.





Effective
May 14, 2010, the Company amended its Articles of Incorporation to change its
name from “E-Dispatch Inc.” to “First China Pharmaceutical Group,
Inc.”





Note
2 – Summary of Significant Accounting Policies





Basis
of presentation





The
accompanying unaudited interim financial statements and related notes have been
prepared in accordance with accounting principles generally accepted in the
United States of America (“U.S. GAAP”) for interim financial information, and
with the rules and regulations of the United States Securities and Exchange
Commission (“SEC”) to Form 10-Q and Article 8 of Regulation
S-X.  Accordingly, they do not include all of the information and
footnotes required by U.S. GAAP for complete financial
statements.  The unaudited interim financial statements furnished
reflect all adjustments (consisting of normal recurring accruals) which are, in
the opinion of management, necessary to a fair statement of the results for the
interim periods presented.  Unaudited interim results are not
necessarily indicative of the results for the full fiscal year.  These
financial statements should be read in conjunction with the financial statements
of the Company for the fiscal year ended March 31, 2010 and notes thereto
contained in the information as part of the Company’s Annual Report on Form 10-K
filed with the SEC on May 10, 2010.





Development
stage company





The
Company is a development stage company as defined by section 810-10-20 of the
FASB Accounting Standards Codification.  The Company is still devoting
substantially all of its efforts on establishing the business and its planned
principal operations have not commenced.  All losses accumulated since
inception have been considered as part of the Company’s exploration stage
activities.





Use
of Estimates





The
preparation of financial statements in conformity with generally accepted
accounting principles of the United States requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
year.  The more significant areas requiring the use of estimates
include asset impairment, stock-based compensation, and future income tax
amounts.  Management bases its estimates on historical experience and
on other assumptions considered to be reasonable under the
circumstances.  However, actual results may differ from the
estimates.





Fiscal
year end





The
Company elected March 31 as its fiscal year ending date.




6





Cash
equivalents





The
Company considers all highly liquid investments with maturities of three months
or less at the time of purchase to be cash equivalents.





Fair
value of financial instruments





The
Company follows paragraph 825-10-50-10 of the FASB Accounting Standards
Codification for disclosures about fair value of its financial instruments and
paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph
820-10-35-37”) to measure the fair value of its financial
instruments.  Paragraph 820-10-35-37 establishes a framework for
measuring fair value in accounting principles generally accepted in the United
States of America (U.S. GAAP), and expands disclosures about fair value
measurements.  To increase consistency and comparability in fair value
measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair
value hierarchy which prioritizes the inputs to valuation techniques used to
measure fair value into three (3) broad levels.  The fair value
hierarchy gives the highest priority to quoted prices (unadjusted) in active
markets for identical assets or liabilities and the lowest priority to
unobservable inputs.  The three (3) levels of fair value hierarchy
defined by Paragraph 820-10-35-37 are described below:





Level
      1
            Quoted
      market prices available in active markets for identical assets or
      liabilities as of the reporting
date.





Level
      2
            Pricing
      inputs other than quoted prices in active markets included in Level 1,
      which are either directly or indirectly observable as of the reporting
      date.





Level
      3
            Pricing
      inputs that are generally observable inputs and not corroborated by market
      data.





The
carrying amounts of the Company’s financial assets and liabilities, such as
cash, prepaid expenses, accounts payable and accrued liabilities,
approximate their fair values because of the short maturity of these
instruments.





The
Company does not have any assets or liabilities measured at fair value on a
recurring or a non-recurring basis.  Consequently, the Company did not
have any fair value adjustments for assets and liabilities measured at fair
value at June 30, 2010 or 2009, nor gains or losses reported in the statement of
operations that are attributable to the change in unrealized gains or losses
relating to those assets and liabilities still held at the reporting date for
the interim period ended June 30, 2010 or 2009.





Income
Taxes





The
Company follows Section 740-10-30 of the FASB Accounting Standards Codification,
which requires recognition of deferred tax assets and liabilities for the
expected future tax consequences of events that have been included in the
financial statements or tax returns.  Under this method, deferred tax
assets and liabilities are based on the differences between the financial
statement and tax bases of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to
reverse.  Deferred tax assets are reduced by a valuation allowance to
the extent management concludes it is more likely than not that the assets will
not be realized.  Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or
settled.  The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in the Statements of Operations in the period
that includes the enactment date.





The
Company adopted section 740-10-25 of the FASB Accounting Standards Codification
(“Section 740-10-25”).  Section 740-10-25 addresses the determination
of whether tax benefits claimed or expected to be claimed on a tax return should
be recorded in the financial statements.  Under Section 740-10-25, the
Company may recognize the tax benefit from an uncertain tax position only if it
is more likely than not that the tax position will be sustained on examination
by the taxing authorities, based on the technical merits of the
position.  The tax benefits recognized in the financial statements
from such a position should be measured based on the largest benefit that has a
greater than fifty percent (50%) likelihood of being realized upon ultimate
settlement.  Section 740-10-25 also provides guidance on
de-recognition, classification, interest and penalties on income taxes,
accounting in interim periods and requires increased disclosures.  The
Company had no material adjustments to its liabilities for unrecognized income
tax benefits according to the provisions of Section 740-10-25.


7





Net
Loss Per Common Share





Net loss
per common share is computed pursuant to section 260-10-45 of the FASB
Accounting Standards Codification.  Basic net loss per share is
computed by dividing net loss by the weighted average number of shares of common
stock outstanding during the period.  Diluted net loss per share is
computed by dividing net loss by the weighted average number of shares of common
stock and potentially outstanding shares of common stock during each
period.  There were no potentially dilutive shares outstanding as of
June 30, 2010 or 2009.





Commitments
and Contingencies





The
Company follows subtopic 450-20 of the FASB Accounting Standards Codification to
report accounting for contingencies.  Liabilities for loss
contingencies arising from claims, assessments, litigation, fines and penalties
and other sources are recorded when it is probable that a liability has been
incurred and the amount of the assessment can be reasonably
estimated.





Cash
Flows Reporting





The
Company adopted paragraph 230-10-45-24 of the FASB Accounting Standards
Codification for cash flows reporting, classifies cash receipts and payments
according to whether they stem from operating, investing, or financing
activities and provides definitions of each category, and uses the indirect or
reconciliation method (“Indirect method”) as defined by paragraph 230-10-45-25
of the FASB Accounting Standards Codification to report net cash flow from
operating activities by adjusting net income to reconcile it to net cash flow
from operating activities by removing the effects of (a) all deferrals of past
operating cash receipts and payments and all accruals of expected future
operating cash receipts and payments and (b) all items that are included in net
income that do not affect operating cash receipts and payments.





Subsequent
Events





The
Company follows the guidance in Section 855-10-50 of the FASB Accounting
Standards Codification for the disclosure of subsequent events. The Company will
evaluate subsequent events through the date when the financial statements
were issued.  Pursuant to ASU 2010-09 of the FASB Accounting Standards
Codification, the Company as an SEC filer considers its financial statements
issued when they are widely distributed to users, such as through filing them on
EDGAR.





Recently
issued accounting pronouncements





In
January 2010, the FASB issued the FASB Accounting Standards Update No.
2010-01 “Equity Topic 505 –
Accounting for Distributions to Shareholders with Components of Stock and
Cash”, which clarify that the stock portion of a distribution to
shareholders that allows them to elect to receive cash or stock with a potential
limitation on the total amount of cash that all shareholders can elect to
receive in the aggregate is considered a share issuance that is reflected in EPS
prospectively and is not a stock dividend for purposes of applying Topics 505
and 260 (Equity and Earnings Per Share (“EPS”)).  Those distributions
should be accounted for and included in EPS calculations in accordance with
paragraphs 480-10-25- 14 and 260-10-45-45 through 45-47 of the FASB Accounting
Standards codification.  The amendments in this Update also provide a
technical correction to the Accounting Standards Codification.  The
correction moves guidance that was previously included in the Overview and
Background Section to the definition of a stock dividend in the Master
Glossary.  That guidance indicates that a stock dividend takes nothing
from the property of the corporation and adds nothing to the interests of the
stockholders.  It also indicates that the proportional interest of
each shareholder remains the same, and is a key factor to consider in
determining whether a distribution is a stock dividend.





In
January 2010, the FASB issued the FASB Accounting Standards Update No.
2010-02 “Consolidation Topic
810 – Accounting and Reporting for Decreases in Ownership of a Subsidiary – a
Scope Clarification”, which provides amendments to Subtopic 810-10 and
related guidance within U.S. GAAP to clarify that the scope of the decrease in
ownership provisions of the Subtopic and related guidance applies to the
following:





1.
            A
      subsidiary or group of assets that is a business or nonprofit
      activity.


2.
            A
      subsidiary that is a business or nonprofit activity that is transferred to
      an equity method investee or joint
venture.


3.
            An
      exchange of a group of assets that constitutes a business or nonprofit
      activity for a noncontrolling interest in an entity (including an equity
      method investee or joint
venture).


8




The
amendments in this Update also clarify that the decrease in ownership guidance
in Subtopic 810-10 does not apply to the following transactions even if they
involve businesses:





1.
            Sales
      of in substance real estate.  Entities should apply the sale of
      real estate guidance in Subtopics 360-20 (Property, Plant, and Equipment)
      and 976-605 (Retail/Land) to such
transactions.


2.
            Conveyances
      of oil and gas mineral rights.  Entities should apply the
      mineral property conveyance and related transactions guidance in Subtopic
      932-360 (Oil and Gas-Property, Plant, and Equipment) to such
      transactions.




If a
decrease in ownership occurs in a subsidiary that is not a business or nonprofit
activity, an entity first needs to consider whether the substance of the
transaction causing the decrease in ownership is addressed in other U.S. GAAP,
such as transfers of financial assets, revenue recognition, exchanges of
nonmonetary assets, sales of in substance real estate, or conveyances of oil and
gas mineral rights, and apply that guidance as applicable.  If no
other guidance exists, an entity should apply the guidance in Subtopic
810-10.





In
January 2010, the FASB issued the FASB Accounting Standards Update No.
2010-06 “Fair Value
Measurements and Disclosures (Topic 820) Improving Disclosures about Fair Value
Measurements”, which provides amendments to Subtopic 820-10
that require new disclosures as follows:




1.
            Transfers
      in and out of Levels 1 and 2. A reporting entity should disclose
      separately the amounts of significant transfers in and out of Level 1 and
      Level 2 fair value measurements and describe the reasons for the
      transfers.


2.
            Activity
      in Level 3 fair value measurements. In the reconciliation for fair value
      measurements using significant unobservable inputs (Level 3), a reporting
      entity should present separately information about purchases, sales,
      issuances, and settlements (that is, on a gross basis rather than as one
      net number).





This Update provides amendments to
Subtopic 820-10 that clarify existing disclosures as
follows:




1.
            Level of disaggregation. A
      reporting entity should provide fair value measurement disclosures for
      each class of assets andliabilities. A class is often a
      subset of assets or liabilities within a line item in the statement of
      financial position. A reporting entity needs to use judgment in
      determining the appropriate classes of assets and
      liabilities.


2.
            Disclosures about inputs and valuation techniques. A
      reporting entity should provide disclosures about the valuation techniques
      and inputs used to measure fair value for both recurring and nonrecurring
      fair value measurements. Those disclosures are required for fair value
      measurements that fall in either Level
      2 or Level 3.





This
Update also includes conforming amendments to the guidance on employers'
disclosures about postretirement benefit plan assets (Subtopic
715-20).  The conforming amendments to Subtopic 715-20 change the
terminology from major
categoriesof assets to classesof assets and provide
a cross reference to the guidance in Subtopic 820-10 on how to determine
appropriate classes to present fair value disclosures.  The new
disclosures and clarifications of existing disclosures are effective for interim
and annual reporting periods beginning after December 15, 2009, except for the
disclosures about purchases, sales, issuances, and settlements in the roll
forward of activity in Level 3 fair value measurements.  Those
disclosures are effective for fiscal years beginning after December 15, 2010,
and for interim periods within those fiscal years.





In
February 2010, the FASB issued the FASB Accounting Standards Update No.
2010-09 “Subsequent Events
(Topic 855) Amendments to Certain Recognition and Disclosure
Requirements”, which provides amendments to Subtopic 855-10 as
follows:





1.
            An
      entity that either (a) is an SEC filer or (b) is a conduit bond obligor
      for conduit debt securities that are traded in a public market (a domestic
      or foreign stock exchange or an over-the-counter market, including local
      or regional markets) is required to evaluate subsequent events through the
      date that the financial statements are issued. If an entity meets neither
      of those criteria, then it should evaluate subsequent events through the
      date the financial statements are available to be
  issued.


2.
            An
      entity that is an SEC filer is not required to disclose the date through
      which subsequent events have been evaluated. This change alleviates
      potential conflicts between Subtopic 855-10 and the SEC's
      requirements.


3.
            The
      scope of the reissuance disclosure requirements is refined to include
      revised financial statements only. The term revised financial statementsis added to the glossary of Topic 855.  Revised financial
      statements include financial statements revised either as a result of
      correction of an error or retrospective application of U.S. generally
      accepted accounting principles.


9





All of
the amendments in this Update are effective upon issuance of the final Update,
except for the use of the issued date for conduit debt obligors. That amendment
is effective for interim or annual periods ending after June 15,
2010.





In
April 2010, the FASB issued the FASB Accounting Standards Update No.
2010-17 “Revenue Recognition —
Milestone Method (Topic 605) Milestone Method of Revenue Recognition”,
which provides guidance on the criteria that should be met for determining
whether the milestone method of revenue recognition is appropriate.  A
vendor can recognize consideration that is contingent upon achievement of a
milestone in its entirety as revenue in the period in which the milestone is
achieved only if the milestone meets all criteria to be considered
substantive.





Determining
whether a milestone is substantive is a matter of judgment made at the inception
of the arrangement. The following criteria must be met for a milestone to be
considered substantive. The consideration earned by achieving the milestone
should:





1.
            Be
      commensurate with either of the
following:





a.
            The
      vendor's performance to achieve the milestone;
  or


b.
            The
      enhancement of the value of the item delivered as a result of a specific
      outcome resulting from the vendor's performance to achieve the
      milestone.





2.
            Relate
      solely to past performance.





3.
            Be
      reasonable relative to all deliverables and payment terms in the
      arrangement.





A
milestone should be considered substantive in its entirety.  An
individual milestone may not be bifurcated.  An arrangement may
include more than one milestone, and each milestone should be evaluated
separately to determine whether the milestone is substantive. Accordingly, an
arrangement may contain both substantive and nonsubstantive
milestones.





A
vendor's decision to use the milestone method of revenue recognition for
transactions within the scope of the amendments in this Update is a policy
election.  Other proportional revenue recognition methods also may be
applied as long as the application of those other methods does not result in the
recognition of consideration in its entirety in the period the milestone is
achieved.





A vendor
that is affected by the amendments in this Update is required to provide all of
the following disclosures:





1.
            A
      description of the overall
arrangement.


2.
            A
      description of each milestone and related contingent
      consideration.


3.
            A
      determination of whether each milestone is considered
      substantive.


4.
            The
      factors that the entity considered in determining whether the milestone or
      milestones are substantive.


5.
            The
      amount of consideration recognized during the period for the milestone or
      milestones.





The
amendments in this Update are effective on a prospective basis for milestones
achieved in fiscal years, and interim periods within those years, beginning on
or after June 15, 2010.  Early adoption is permitted.  If a
vendor elects early adoption and the period of adoption is not the beginning of
the entity's fiscal year, the entity should apply the amendments retrospectively
from the beginning of the year of adoption.  Additionally, a vendor
electing early adoption should disclose the following information at a minimum
for all previously reported interim periods in the fiscal year of
adoption:





1.
            Revenue.


2.
            Income
      before income taxes.


3.
            Net
      income.


4.
            Earnings
      per share.


5.
            The
      effect of the change for the captions
presented.





A vendor
may elect, but is not required, to adopt the amendments in this Update
retrospectively for all prior periods.





Management
does not believe that any other recently issued, but not yet effective
accounting pronouncements, if adopted, would have a material effect on the
accompanying consolidated financial statements.


10





Note
3 – Going Concern





The accompanying financial statements
have been preparedassuming that the Company will continue as a going
concern.  As
reflected in the accompanying financial statements, the Company had a deficit
accumulated during the development stage of $72,958 at June 30, 2010, a net loss
from operations of $4,347 and net cash used in operations of $8,544 for the
interim period ended June 30, 2010, respectively.





While the
Company is attempting to generate sufficient revenues, the Company’s cash
position may not be enough to support the Company’s daily
operations.  Management intends to raise additional funds by way of a
public or private offering.  Management believes that the actions
presently being taken to further implement its business plan and generate
sufficient revenues provide the opportunity for the Company to continue as a
going concern.  While the Company believes in the viability of its
strategy to increase revenues and in its ability to raise additional funds,
there can be no assurances to that effect.  The ability of the Company
to continue as a going concern is dependent upon the Company’s ability to
further implement its business plan and generate sufficient
revenues.  The financial statements do not include any adjustments
that might be necessary if the Company is unable to continue as a going
concern.





Note
4 – Due to Stockholder





The
amount owing to stockholder is unsecured, non-interest bearing and has no
specific terms of repayment.





Note
5 – Stockholders’ Deficit





Effective May 17, 2010, the Board of
Directors effectuated a 25-for-1 forward stock split of the Company’s
outstanding shares of common stock.





All share
and per share amounts in these financial statements have been adjusted to give
retroactive effect to the forward stock split.





Following the forward stock split, the
Company has 45,000,000 shares of common stock outstanding.





On June 25, 2010, pursuant to approvals
by stockholders owning in excess of a majority of the voting power of the
Company’s outstanding shares, the Company amended its articles of incorporation
to increase the total number of authorized shares of common stock from
100,000,000 to 200,000,000 shares.





Note
6 – Subsequent Events





The
Company has evaluated all events that occurred after the balance sheet date of
June 30, 2010 throughthe date these financial
statements were issued.   The Management of the Company
determined that there were no reportable events that occurred during that
subsequent period to be disclosed or recorded.


11




ITEM
      2.
            MANAGEMENT’S
      DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
      OPERATIONS




The
following discussion should be read in conjunction with the information
contained in our financial statements and the notes thereto, which form an
integral part of the financial statements, which are attached
hereto.




The
financial statements mentioned above have been prepared in conformity with
accounting principles generally accepted in the United States of America and are
stated in United States dollars.




This
Quarterly Report on Form 10-Q contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”),
Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),
and Section 21E of the Securities Exchange Act of 1934, as amended, (the
“Exchange Act”), about our expectations, beliefs or intentions regarding our
business, financial condition, results of operations, strategies or prospects.
You can identify forward-looking statements by the fact that these statements do
not relate strictly to historical or current matters. Rather, forward-looking
statements relate to anticipated or expected events, activities, trends or
results as of the date they are made. Forward-looking statements are often
identified by words such as: believe, expect, estimate, anticipate, intend,
project and similar expressions, or words which, by their nature. Because
forward-looking statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that could cause
our actual results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause our actual
operations or results to differ materially from the operations and results
anticipated in forward-looking statements. Details about the various risks
affecting the Company may be found throughout this Quarterly Report on Form
10-Q, as well as in our Annual Report on Form 10-K for the year ended March 31,
2010. You should not place undue certainty on these forward-looking statements,
which apply only as of the date of this Form 10-Q. We do not undertake any
obligation to update forward-looking statements. We intend that all
forward-looking statements be subject to the safe harbor provisions of PSLRA.
These forward-looking statements are only predictions and reflect our views as
of the date they are made with respect to future events and financial
performance.




Overview




First
China Pharmaceutical Group, Inc., formerly known as E-Dispatch Inc. (the
“Company”, “we”, “our” or “us”) is a development stage company with limited
operations and no revenues from our business operations.  We were
formed as E-Dispatch Inc. in Nevada on July 31, 2007.  Effective May
14, 2010, we amended our Articles of Incorporation to change our name from
“E-Dispatch Inc.” to “First China Pharmaceutical Group, Inc.”




We were
formed to develop and sell a low-cost taxi dispatch system. However, to date, we
have been unable to raise additional funds to implement our operations, and we
do not believe that we currently have sufficient resources to do so without
additional funding.  As a result of the current difficult economic
environment and our lack of funding to implement our business plan, our Board of
Directors analyzed strategic alternatives available to our company to continue
as a going concern.  Such alternatives include raising additional debt
or equity financing or consummating a merger or acquisition with a partner that
may involve a change in our business plan.




Although
our Board of Directors’ preference would be to obtain additional funding to
develop our taxi dispatch system, the Board believes that it must consider all
viable strategic alternatives that are in the best interests of our
shareholders.  Such strategic alternatives include a merger,
acquisition, share exchange, asset purchase, or similar transaction in which our
present management will no longer be in control of our Company and our business
operations will be replaced by that of our transaction partner.  We
believe we would be an attractive candidate for such a business combination due
to the perceived benefits of being a publicly registered company, thereby
providing a transaction partner access to the public marketplace to raise
capital.




On May 14, 2010,we entered into a Letter of Intent
(“LOI”) with First China Pharmaceutical Group, Limited, a Hong Kong company
(“FCPG HK”). FCPG HK’s wholly-owned subsidiary,Kun Ming Xin Yuan Tang
Pharmacies Co. Ltd., a company organized under the laws of the People’s Republic
of China (“XYT”) specializes in bulk sales of Chinese patent drug, antibiotics,
bio-chemicals, chemical preparations, biologicals in Yunnan Province, People’s
Republic of China.





Under
certain non-binding terms of the LOI, the parties agree to act towards entering
into a definitive agreement whereby we would acquire all of the issued and
outstanding shares of FCPG HK in exchange for the issuance to the sole
stockholder of FCPG HK or his nominees of twenty-five percent (25%) ownership
interest in our Company (on a post-closing basis).  Upon closing of
the voluntary share exchange transaction, both FCPG HK and XYT would become our
wholly owned subsidiaries and we will acquire the business and operations of
XYT.  The closing date for transaction shall be thirty days from the
date FCPG HK completes an audit of its financial statements as required under
U.S. securities laws.


12




On May 17, 2010, we effected a 25-for-1
forward stock split of all of our issued and outstanding shares of common stock
and on June 25, 2010, our stockholders approved a proposal to amend our
articles of incorporation to increase the total number of authorized shares of
our common stock from 100,000,000 to 200,000,000.




Critical
Accounting Policies




The
discussion and analysis of our financial condition and results of operations are
based upon our financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States of
America.  We believe certain critical accounting policies affect our
more significant judgments and estimates used in the preparation of our
financial statements.  A description of our significant accounting
policies is set forth in the notes to our audited consolidated financial
statements for the year ended March 31, 2010. As of, and for the three months
ended June 30, 2010, there have been no material changes or updates to our
critical accounting policies.




Results
of Operations




The
following discussion of the financial condition, results of operations, cash
flows and changes in our financial position should be read in conjunction with
our audited consolidated financial statements and notes thereto for the fiscal
year ended March 31, 2010.




Revenues




We had no
revenues for the period from July 31, 2007 (date of inception), through June 30,
2010.




Expenses




Our
expenses for the three month periods ended June 30, 2010 and 2009, were $4,347
and $2,850, respectively.  During the period from July 31, 2007 (date
of inception) through June 30, 2010, we have incurred expenses of
$72,958.  These expenses were comprised primarily of general and
administrative, and legal and accounting expenses, as well as banking
fees.




Net
Income (Loss)




Our net
losses for the three-month periods ended June 30, 2010 and 2009 were $4,347 and
$2,850, respectively. During the period from July 31, 2007 (date of inception)
through June 30, 2010, we have incurred a net loss of $72,958.  This
loss consisted primarily of incorporation costs, legal and accounting fees,
consulting fees, website hosting costs, and administrative
expenses.




Liquidity
and Capital Resources




As of
June 30, 2010, we had cash and cash equivalents of $27 and current liabilities
of $23,002.  Our cash needs are primarily for working capital to
support our operations and execute our business objectives. We presently finance
our operations through the private placement of equity and debt securities. We
have limited capital needs in the next 6 months as we have very limited
operations.  We believe that our existing capital resources is
sufficient to meet our current obligations and operating requirements, but will
not be sufficient to meet any aggressive growth plans. We will consider debt or
equity offerings or institutional borrowing as potential means of financing,
however, there are no assurances that we will be successful or that we will
obtain terms that are favorable to us.




Net cash
used in operating activities for the three months ended June 30, 2010 was $8,544
compared with net cash used in operating activities of $1,563 for the same
period in 2009. Net cash used in operating activities for the three months ended
June 30, 2010 was mainly due to increased professional fees related to changes
in the Company’s legal structure and name.  Net cash used in operating
activities for the same period in 2009 was mainly due to increase in prepaid
expenses, accounts payable and accrued liabilities.




Net cash
used in investing activities was $0 for the three months ended June 30, 2010 and
2009.




Net cash
provided by financing activities was $1,240 for the three months ended June 30,
2010, compared with $0 net cash provided by financing activities for the same
period in 2009.


13




Off-Balance
Sheet Arrangements




We have
not entered into any other financial guarantees or other commitments to
guarantee the payment obligations of any third parties.  We have not
entered into any derivative contracts that are indexed to our shares and
classified as shareholder’s equity or that are not reflected in our consolidated
financial statements.  Furthermore, we do not have any retained or
contingent interest in assets transferred to an unconsolidated entity that
serves as credit, liquidity or market risk support to such entity.  We
do not have any variable interest in any unconsolidated entity that provides
financing, liquidity, market risk or credit support to us or engages in leasing,
hedging or research and development services with us.




ITEM
3.           QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS




We do not
use derivative financial instruments and have no foreign exchange contracts. Our
financial instruments consist of cash, accounts payable, accrued expenses, debt
and derivative liability. The objective of our policies is to mitigate potential
income statement, cash flow and fair value exposures resulting from possible
future adverse fluctuations in rates. We evaluate our exposure to market risk by
assessing the anticipated near-term and long-term fluctuations in interest rates
and foreign exchange rates. This evaluation includes the review of leading
market indicators, discussions with financial analysts and investment bankers
regarding current and future economic conditions and the review of market
projections as to expected future rates.




We did
not experience any material changes in interest rate exposures during 2009 and
2010, to date.  Hence, the effect of the fluctuations of the interest
rates is considered minimal to our business operations. Based upon economic
conditions and leading market indicators at June 30, 2010, we do not foresee a
significant adverse change in interest rates in the near future and do not use
interest rate derivatives to manage exposure to interest rate
changes.




ITEM
4.           CONTROLS AND
PROCEDURES




Evaluation
of Disclosure Controls and Procedures




We
carried out an evaluation, under the supervision and with the participation of
our management, including our Chief Executive Officer along with our Chief
Financial Officer, of the effectiveness of the design of our disclosure controls
and procedures (as defined by Exchange Act Rule 13a-15(e) and 15a-15(e)) as of
June 30, 2010 pursuant to Exchange Act Rule 13a-15.  Based upon that
evaluation, our Principal Executive Officer along with our Principal Financial
Officer concluded that our disclosure controls and procedures are not effective
as of the end of the period covered by this report in ensuring that information
required to be disclosed by us in reports that we file or submit under the
Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission’s rules and
forms.  This conclusion is based on findings that constituted material
weaknesses.  A material weakness is a deficiency, or a combination of
control deficiencies, in internal control over financial reporting such that
there is a reasonable possibility that a material misstatement of the Company’s
interim financial statements will not be prevented or detected on a timely
basis.




These
material weaknesses include: (1) lack of a functioning audit committee due to a
lack of a majority of independent members and a lack of a majority of outside
directors on our board of directors, resulting in ineffective oversight in the
establishment and monitoring of required internal controls and procedures; (2)
inadequate segregation of duties consistent with control objectives; and (3)
ineffective controls over period end financial disclosure and reporting
processes.




Our
Principal Executive Officer and Principal Financial Officer believe that the
material weaknesses set forth in items (2) and (3) above did not have an effect
on our financial results. However, our Principal Executive Officer and Principal
Financial Officer believe that the lack of a functioning audit committee and the
lack of a majority of outside directors on our board of directors results in
ineffective oversight in the establishment and monitoring of required internal
controls and procedures, which could result in a material misstatement in our
financial statements in future periods.




Management’s
Remediation Initiatives




In an
effort to remediate the identified material weaknesses and other deficiencies
and enhance our internal controls, we have initiated, or plan to initiate, the
following series of measures:




We will
create a position to segregate duties consistent with control objectives and
will increase our personnel resources and technical accounting expertise within
the accounting function when funds are available to us. And, we plan to appoint
one or more outside directors to our board of directors who shall be appointed
to an audit committee resulting in a fully functioning audit committee who will
undertake the oversight in the establishment and monitoring of required internal
controls and procedures such as reviewing and approving estimates and
assumptions made by management when funds are available to us.


14




Management
believes that the appointment of one or more outside directors, who shall be
appointed to a fully functioning audit committee, will remedy the lack of a
functioning audit committee and a lack of a majority of outside directors on our
Board.




We
anticipate that these initiatives will be at least partially, if not fully,
implemented by March 31, 2011. Additionally, we plan to test our updated
controls and remediate our deficiencies by March 31, 2011.




Changes
in Internal Control Over Financial Reporting




There was
no change in our internal controls over financial reporting that occurred during
the fiscal quarter ended June 30, 2010, which has materially affected, or is
reasonably likely to materially affect, our internal controls over financial
reporting.




Limitations
on the Effectiveness of Controls




Because
of its inherent limitations, internal control over financial reporting may not
prevent or detect misstatements. Projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate. All internal control systems, no matter
how well designed, have inherent limitations. Therefore, even those systems
determined to be effective can provide only reasonable assurance with respect to
financial statement preparation and presentation.


15


PART
II - OTHER INFORMATION




ITEM
      1.
            LEGAL
      PROCEEDINGS




None.




ITEM
      1A.
            RISK
      FACTORS




Not
Applicable.




ITEM 2.
            UNREGISTERED
      SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS




None.




ITEM
      3.
            DEFAULTS
      UPON SENIOR SECURITIES




None.




ITEM
      4.
            REMOVED
      AND RESERVED




ITEM
      5.
            OTHER
      INFORMATION




None.




ITEM
      6.
            EXHIBITS




The
following exhibits are included as part of this report by
reference:




Exhibit
                  Number
                
                Description3.1
                
                Articles
      of Incorporation of the Registrant, dated July 31, 2007 (incorporated by
      reference from Exhibit 3.1 of the Registrant’s Registration Statement on
      Form S-1 filed May 28, 2008)3.2
                
                Amendment
      to Articles of Incorporation of the Registrant, as filed with the
      Secretary of State of the State of Nevada on May 14, 2010 (incorporated by
      reference from Exhibit 3.1(a) of the Registrant’s Current Report on Form
      8-K filed on May 17, 2010)3.3
                
                Amendment
      to the Articles of Incorporation of the Registrant, as filed with the
      Secretary of State of the State of Nevada on June 29, 2010 (incorporated
      by reference from Exhibit 3.1(a) of the Registrant’s Current Report on
      Form 8-K filed on June 30, 2010)3.4
                
                Amended
      and Restated Bylaws of the Company, as adopted June 1, 2010 (incorporated
      by reference from Exhibit 3.2 of the Registrant’s Current Report on Form
      8-K filed on June 30, 2010)4.1
                
                Form
      of Stock Specimen (incorporated by reference to Exhibit 4.1 of the
      Registrant’s Registration Statement on Form S-1 filed on May 28,
      2008)31.1
                
                Certification
      of Principal Executive Officer pursuant to Section 302 of the
      Sarbanes-Oxley Act of 2002.31.2
                
                Certification
      of Principal Financial Officer and Principal Accounting Officer pursuant
      to Section 302 of the Sarbanes-Oxley Act of 2002.32.1
                
                Certification
      of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as
      Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
      2002.32.2
                
                Certification
      of Principal Financial Officer and Principal Accounting Officer pursuant
      to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
      Sarbanes-Oxley Act of
2002.




16





SIGNATURES




Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.




FIRST
      CHINA PHARMACEUTICAL GROUP, INC.Date:  August
      6, 2010
            /s/ Aidan HwuangName:  Aidan
      HwuangTitle:  President
      and Director(Principal
      Executive Officer)Date:  August
      6, 2010
            /s/ Aidan HwuangName:  Aidan
      HwuangTitle:  Chief
      Financial Officer(Principal
      Financial Officer and Principal Accounting
  Officer)




17